Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- cyclophosphamide
- Flagyl ER (metronidazole)
Interactions between your drugs
cycloPHOSphamide metroNIDAZOLE
Applies to: cyclophosphamide, Flagyl ER (metronidazole)
Using cycloPHOSphamide together with metroNIDAZOLE may increase the effects of cycloPHOSphamide. This could cause encephalopathy (swelling of the brain) with hallucinations and seizures. Contact your doctor if your condition worsens. You may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
metroNIDAZOLE food
Applies to: Flagyl ER (metronidazole)
Consumption of alcoholic beverages or products containing alcohol or propylene glycol during treatment with metroNIDAZOLE is not recommended. Doing so may occasionally trigger a reaction in some patients similar to the disulfiram reaction, which includes unpleasant effects such as flushing, throbbing in head and neck, throbbing headache, difficulty breathing, nausea, vomiting, sweating, thirst, chest pain, rapid heartbeat, palpitation, low blood pressure, dizziness, lightheadedness, blurred vision, and confusion. Rarely, more severe reactions may include abnormal heart rhythm, heart attack, heart failure, unconsciousness, convulsions, and even death. Patients treated with metroNIDAZOLE should continue to avoid using any products containing alcohol or propylene glycol for at least 3 days until after completion of therapy. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.